A Phase 3 interventional study of brentuximab vedotin and doxorubicin in Hodgkin Lymphoma, sponsored by Takeda. Completed at 215 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies testing Brentuximab Vedotin in Hodgkin Disease — 14 open to participants now, 28 under way, 8 of them phase 3. Brentuximab Vedotin · Hodgkin Disease.
Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, this one is the 3rd largest by enrollment, is one of 7 that started in 2012, is one of 8 in phase 3, and was the 18th registered.
1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.
Browse Hodgkin Disease studies →14 of the 80 studies testing Brentuximab Vedotin in Hodgkin Disease are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
University of Miami · Sites in United States
Ages 18–60
Children's Cancer Group, China · Sites in China
Ages 2–35
Takeda · Sites in India
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 56 · Phase 3 11 · Phase 4 2
First in 2006; this study’s year is marked. 7 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,334 is above the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.
Median enrollment 52 across the 80 interventional studies. Of the 46 that completed or were terminated, 26 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 80 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
15 studies in Hodgkin Disease by Takeda: 3 open now, 4 under way, none of them phase 3. Of 10 finished, 6 (60%) have results posted.
Among the 15 studies in Hodgkin Disease by Takeda, this one is one of 2 that started in 2012, is one of 2 in phase 3, and was the 4th registered.
Takeda’s Hodgkin Disease studies by the year they started, since 1997.
7 of the studies testing Brentuximab Vedotin in Hodgkin Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05180097Canadian Cancer Trials GroupPembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma | 2026-12-31 |
| NCT03755804St. Jude Children's Research HospitalPediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | 2027-01-01 |
| NCT06377566Memorial Sloan Kettering Cancer CenterA Study of BV-AVD in People With Bulky Hodgkin Lymphoma | 2027-04 |
| NCT04561206City of Hope Medical CenterBrentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | 2027-10-02 |
| NCT05404945University of VirginiaFitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above | 2027-10-03 |
Add all 7 to your calendar (.ics) → With an account.
Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, from their registry updates:
Among Takeda’s 15 in Hodgkin Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCETRIS®) plus AVD (doxorubicin [Adriamycin], vinblastine, and dacarbazine; abbreviated A+AVD) versus that obtained with ABVD (doxorubicin [Adriamycin],bleomycin, vinblastine, and dacarbazine) for the frontline treatment of advanced classical Hodgkin lymphoma(HL)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Please note that there are additional exclusion criteria. The study center will determine if you meet all of the criteria.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A+AVD consists of brentuximab vedotin (ADCETRIS®) 1.2 milligram per kilogram (mg/kg) plus doxorubicin 25 milligram per square meter (mg/m\^2), vinblastine 6 mg/m\^2, and dacarbazine (DTIC) 375 mg/m\^2.
Drug: brentuximab vedotin · Drug: doxorubicin · Drug: vinblastine · Drug: dacarbazine
ABVD consists of doxorubicin 25 mg/m\^2, bleomycin 10 units per square meter (units/m\^2), vinblastine 6 mg/m\^2, and dacarbazine (DTIC) 375 mg/m\^2.
Drug: doxorubicin · Drug: bleomycin · Drug: vinblastine · Drug: dacarbazine
Brentuximab vedotin (ADCETRIS®)1.2 mg/kg by IV infusion on Days 1 and 15 of each 28-day cycle.
Also known as: ADCETRIS®, SGN-35
Doxorubicin: 25 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
Also known as: Adriamycin
Bleomycin: 10 units/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
Vinblastine: 6 mg/m2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
Dacarbazine (DTIC): 375 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
Also known as: DTIC
Modified Progression-free Survival (mPFS) Per Independent Review Facility (IRF)
mPFS was defined as the time from the date of randomization to the date of the first of documentation of progressive disease (PD), death due to any cause, or for participants who were confirmed non complete responders per IRF, receipt of subsequent anticancer therapy for Hodgkin lymphoma (HL) after completion of frontline therapy. PD was defined as any new lesion or increase by greater than or equal to (\>=) 50 percent (%) of previously involved sites from nadir. Frontline therapy is the part of standard set of treatments.
Time frame: Baseline until PD or death or receipt of any subsequent anticancer therapy for HL after completion of frontline therapy (approximately up to 4 years)
Overall Survival (OS)
OS was defined as the time from the date of randomization to the date of death. Participants without documented death at the time of analysis were censored at the date last known to be alive.
Time frame: Baseline until death (approximately up to 4 years)
Complete Remission (CR) Rate at the End of Randomized Regimen Per IRF
CR rate at the end of randomized regimen per investigator was defined as the percentage of participants who achieved CR at the end of treatment with randomized regimen (ABVD or A+AVD) as determined by IRF. CR was defined as disappearance of all evidence of disease.
Time frame: Baseline up to end of randomized regimen (approximately 1 year)
Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)
Time frame: Baseline up to 30 days after last dose of study drug (approximately 1 year)
Number of Participants With Abnormal Clinical Laboratory Values
Time frame: Baseline up to 30 days after last dose of study drug (approximately 1 year)
Event-free Survival (EFS) Per IRF
EFS was defined as the time from randomization until any cause of treatment failure: PD, premature discontinuation of randomized treatment for any reason, or death due to any cause, whichever occurs first. PD was defined as any new lesion or increase by \>=50% of previously involved sites from nadir per IRF.
Time frame: Baseline until PD or discontinuation of treatment or death, whichever occurs first (approximately up to 4 years)
Disease-free Survival (DFS) Per IRF
DFS per IRF was defined as the time from CR to disease progression as determined by an IRF or to death from lymphoma or acute toxicity from treatment. CR was defined as disappearance of all evidence of disease.
Time frame: From CR until PD or death (approximately up to 4 years)
Overall Response Rate (ORR) Per IRF
ORR per IRF was defined as the percentage of participants who achieved CR or partial remission (PR) at the end of treatment with randomized regimen (ABVD or A+AVD) as determined by an IRF. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.
Time frame: Baseline up to end of randomized regimen (approximately 1 year)
Duration of Response (DOR) Per IRF
DOR per IRF in participants with response was the time between first documentation of response (PR or CR) and PD as determined by an IRF. PD was defined as any new lesion or increase by \>=50% of previously involved sites from nadir. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.
Time frame: From first documented response until PD (approximately 4 years)
Duration of Complete Remission (DOCR) Per IRF
DOCR per IRF in participants with CR was the time between first documentation of CR and PD as determined by an IRF. PD was defined as any new lesion or increase by \>=50% of previously involved sites from nadir. CR was defined as disappearance of all evidence of disease.
Time frame: From first documentation of CR until PD (approximately 4 years)
Percentage of Participants Not in CR Per IRF Who Received Subsequent Radiation After Completion of Frontline Therapy
CR was defined as disappearance of all evidence of disease as determined by an IRF.
Time frame: Baseline up to end of frontline therapy (approximately 4 years)
Complete Remission (CR) Per IRF Rate at the End of Frontline Therapy
CR rate at the end of frontline therapy per IRF was defined as the percentage of participants who achieved CR at the end of frontline therapy that is after completion of either randomized regimen or alternate frontline therapy as determined by an IRF. CR was defined as disappearance of all evidence of disease.
Time frame: Baseline up to end of frontline therapy (approximately 4 years)
Positron Emission Tomography (PET) Negativity Rate Per IRF at Cycle 2
PET negativity rate at Cycle 2 was defined as the percentage of participants with negative Cycle 2 PET results defined as Deauville score less than or equal to (\<=) 3 at Cycle 2. The Deauville score according to IRF assessment of response was used to evaluate the results of PET scans.
Time frame: Cycle 2 Day 25
A+AVD: Cmax: Maximum Observed Serum Concentration for Brentuximab Vedotin Antibody-drug Conjugate (ADC) and Total Antibody (TAb)
Time frame: Cycle 1 Day 1 and Cycle 3 Day 1: pre-dose and at multiple timepoints (up to 48 hours) post-dose
A+AVD: Cmax: Maximum Observed Plasma Concentration for Brentuximab Vedotin Monomethyl Auristatin E (MMAE)
Time frame: Cycle 1 Day 1 and Cycle 3 Day 1: pre-dose and at multiple timepoints (up to 48 hours) post-dose
A+AVD: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Brentuximab Vedotin ADC and TAb
Time frame: Cycle 1 Day 1: pre-dose and at multiple timepoints (up to 48 hours) post-dose
A+AVD: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Brentuximab Vedotin MMAE
Time frame: Cycle 1 Day 1: pre-dose and at multiple timepoints (up to 48 hours) post-dose
A+AVD: Number of Participants With Antitherapeutic Antibody (ATA) and Neutralizing Antitherapeutic Antibody (nATA) Positive for Brentuximab Vedotin
The nATA positive was defined as positive ATA with neutralizing activity at any postbaseline visit.
Time frame: Baseline up to end of treatment (approximately 1 year)
Change From Baseline in Patient-Reported Outcome (PRO) Scores by mPFS Based on European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-C30 (EORTC QLQ-C30) at EOT
EORTC QLQ-C30 included 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and global health status/QOL scale. It has 28 questions (4-point scale where 1=not at all \[best\] to 4=Very Much \[worst\]) and 2 questions (7-point scale where 1=very poor \[worst\] to 7= excellent \[best\]). Raw scores were converted into scale scores from 0 to 100. For functional scales and global health status/QOL scale, higher scores show better QOL; for symptom scales, lower scores show better QOL. mPFS was time from date of randomization to date of first of documentation of PD, death due to any cause, or for participants who were confirmed non complete responders per IRF, receipt of subsequent anticancer therapy for HL after completion of frontline therapy. PD is any new lesion or increase by \>=50% of previously involved sites from nadir.
Time frame: Baseline up to end of treatment (approximately 1 year)
Participants took part in the study at 218 investigative sites in Asia Pacific, Europe, Latin America, and North America from 09 November 2012 to the primary completion date of 20 April 2017.
| Milestone | A+AVD | ABVD |
|---|---|---|
| Started | 664 | 670 |
| Treated | 662 | 659 |
| Completed | 0 | 0 |
| Not completed | 664 | 670 |
| Withdrew: Ongoing | 601 | 586 |
| Withdrew: Other | 11 | 11 |
| Withdrew: Withdrawal by subject | 36 | 44 |
| Withdrew: Lost to follow-up | 16 | 29 |
mPFS was defined as the time from the date of randomization to the date of the first of documentation of progressive disease (PD), death due to any cause, or for participants who were confirmed non complete responders per IRF, receipt of subsequent anticancer therapy for Hodgkin lymphoma (HL) after completion of frontline therapy. PD was defined as any new lesion or increase by greater than or equal to (\>=) 50 percent (%) of previously involved sites from nadir. Frontline therapy is the part of standard set of treatments.
| months | A+AVD | ABVD |
|---|---|---|
| Modified Progression-free Survival (mPFS) Per Independent Review Facility (IRF) | NA (48.2 to NA) | NA (NA to NA) |
OS was defined as the time from the date of randomization to the date of death. Participants without documented death at the time of analysis were censored at the date last known to be alive.
| months | A+AVD | ABVD |
|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) |
CR rate at the end of randomized regimen per investigator was defined as the percentage of participants who achieved CR at the end of treatment with randomized regimen (ABVD or A+AVD) as determined by IRF. CR was defined as disappearance of all evidence of disease.
| percentage of participants | A+AVD | ABVD |
|---|---|---|
| Complete Remission (CR) Rate at the End of Randomized Regimen Per IRF | 73 | 70 |
| participants | A+AVD | ABVD |
|---|---|---|
| TEAE | 653 | 646 |
| SAE | 284 | 178 |
| participants | A+AVD | ABVD |
|---|---|---|
| Number of Participants With Abnormal Clinical Laboratory Values | 662 | 658 |
EFS was defined as the time from randomization until any cause of treatment failure: PD, premature discontinuation of randomized treatment for any reason, or death due to any cause, whichever occurs first. PD was defined as any new lesion or increase by \>=50% of previously involved sites from nadir per IRF.
| months | A+AVD | ABVD |
|---|---|---|
| Event-free Survival (EFS) Per IRF | NA (43.8 to NA) | NA (NA to NA) |
DFS per IRF was defined as the time from CR to disease progression as determined by an IRF or to death from lymphoma or acute toxicity from treatment. CR was defined as disappearance of all evidence of disease.
| months | A+AVD | ABVD |
|---|---|---|
| Disease-free Survival (DFS) Per IRF | NA (42.1 to NA) | NA (NA to NA) |
ORR per IRF was defined as the percentage of participants who achieved CR or partial remission (PR) at the end of treatment with randomized regimen (ABVD or A+AVD) as determined by an IRF. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.
| percentage of participants | A+AVD | ABVD |
|---|---|---|
| Overall Response Rate (ORR) Per IRF | 86 | 83 |
DOR per IRF in participants with response was the time between first documentation of response (PR or CR) and PD as determined by an IRF. PD was defined as any new lesion or increase by \>=50% of previously involved sites from nadir. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.
| months | A+AVD | ABVD |
|---|---|---|
| Duration of Response (DOR) Per IRF | NA (42.1 to NA) | NA (NA to NA) |
DOCR per IRF in participants with CR was the time between first documentation of CR and PD as determined by an IRF. PD was defined as any new lesion or increase by \>=50% of previously involved sites from nadir. CR was defined as disappearance of all evidence of disease.
| months | A+AVD | ABVD |
|---|---|---|
| Duration of Complete Remission (DOCR) Per IRF | NA (42.1 to NA) | NA (NA to NA) |
CR was defined as disappearance of all evidence of disease as determined by an IRF.
| percentage of participants | A+AVD | ABVD |
|---|---|---|
| Percentage of Participants Not in CR Per IRF Who Received Subsequent Radiation After Completion of Frontline Therapy | 8 | 13 |
CR rate at the end of frontline therapy per IRF was defined as the percentage of participants who achieved CR at the end of frontline therapy that is after completion of either randomized regimen or alternate frontline therapy as determined by an IRF. CR was defined as disappearance of all evidence of disease.
| percentage of participants | A+AVD | ABVD |
|---|---|---|
| Complete Remission (CR) Per IRF Rate at the End of Frontline Therapy | 73 | 71 |
PET negativity rate at Cycle 2 was defined as the percentage of participants with negative Cycle 2 PET results defined as Deauville score less than or equal to (\<=) 3 at Cycle 2. The Deauville score according to IRF assessment of response was used to evaluate the results of PET scans.
| percentage of participants | A+AVD | ABVD |
|---|---|---|
| Positron Emission Tomography (PET) Negativity Rate Per IRF at Cycle 2 | 89 | 86 |
| microgram per milliliter (microgm/mL) | A+AVD |
|---|---|
| Cycle 1 Day 1: ADC | 22.9 ± 6.72 |
| Cycle 3 Day 1: ADC | 23.6 ± 6.81 |
| Cycle 1 Day 1: TAb | 22.6 ± 5.48 |
| Cycle 3 Day 1: TAb | 26.4 ± 6.11 |
| nanogram per milliliter (ng/mL) | A+AVD |
|---|---|
| Cycle 1 Day 1 | 3.20 ± 2.99 |
| Cycle 3 Day 1 | 1.36 ± 0.790 |
| day*microgram per milliliter (day*ug/mL) | A+AVD |
|---|---|
| Cycle 1 Day 1: ADC | 47.4 ± 12.0 |
| Cycle 1 Day 1: TAb | 93.0 ± 25.7 |
| day*nanogram per milliliter (day*ng/mL) | A+AVD |
|---|---|
| A+AVD: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Brentuximab Vedotin MMAE | 25.3 ± 19.2 |
The nATA positive was defined as positive ATA with neutralizing activity at any postbaseline visit.
| participants | A+AVD |
|---|---|
| ATA positive | 109 |
| nATA positive | 12 |
EORTC QLQ-C30 included 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and global health status/QOL scale. It has 28 questions (4-point scale where 1=not at all \[best\] to 4=Very Much \[worst\]) and 2 questions (7-point scale where 1=very poor \[worst\] to 7= excellent \[best\]). Raw scores were converted into scale scores from 0 to 100. For functional scales and global health status/QOL scale, higher scores show better QOL; for symptom scales, lower scores show better QOL. mPFS was time from date of randomization to date of first of documentation of PD, death due to any cause, or for participants who were confirmed non complete responders per IRF, receipt of subsequent anticancer therapy for HL after completion of frontline therapy. PD is any new lesion or increase by \>=50% of previously involved sites from nadir.
| units on scale | A+AVD | ABVD |
|---|---|---|
| Baseline: With mPFS event | 78.15 ± 16.527 | 76.68 ± 18.661 |
| Without mPFS event | 79.85 ± 16.648 | 79.91 ± 16.218 |
| Change at end of treatment: with mPFS event | 2.68 ± 15.434 | 8.58 ± 17.848 |
| Change at end of treatment: without mPFS event | 3.35 ± 17.417 | 6.08 ± 16.141 |
Collected over TEAEs are adverse events that started after the first dose of study drug and no more than 30 days (approximately 1 year) for a serious adverse event after the last dose of study drug. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| A+AVD | 9/662 (1.4%) | 284/662 (42.9%) | 644/662 (97.3%) |
| ABVD | 13/659 (2%) | 178/659 (27%) | 632/659 (95.9%) |
| Event | A+AVD | ABVD |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 114/662 | 43/659 |
| PyrexiaGeneral disorders | 44/662 | 28/659 |
| NeutropeniaBlood and lymphatic system disorders | 19/662 | 4/659 |
| PneumoniaInfections and infestations | 18/662 | 15/659 |
| SepsisInfections and infestations | 14/662 | 4/659 |
| Abdominal painGastrointestinal disorders | 14/662 | 4/659 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 2/662 | 12/659 |
| VomitingGastrointestinal disorders | 11/662 | 3/659 |
| ConstipationGastrointestinal disorders | 11/662 | 6/659 |
| DiarrhoeaGastrointestinal disorders | 11/662 | 1/659 |
| Event | A+AVD | ABVD |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 374/662 | 291/659 |
| NauseaGastrointestinal disorders | 346/662 | 369/659 |
| ConstipationGastrointestinal disorders | 273/662 | 239/659 |
| VomitingGastrointestinal disorders | 212/662 | 183/659 |
| FatigueGeneral disorders | 209/662 | 211/659 |
| Peripheral sensory neuropathyNervous system disorders | 189/662 | 111/659 |
| DiarrhoeaGastrointestinal disorders | 176/662 | 121/659 |
| Neuropathy peripheralNervous system disorders | 174/662 | 85/659 |
| AlopeciaSkin and subcutaneous tissue disorders | 173/662 | 146/659 |
| PyrexiaGeneral disorders | 149/662 | 128/659 |
The intent-to-treat (ITT) population included all participants randomized to treatment.
| Age, Continuous(years) | A+AVD | ABVD | Total |
|---|---|---|---|
| Mean | 38.8 ± 15.83 | 40.2 ± 16.05 | 39.5 ± 15.95 |
| Sex: Female, Male(Participants) | A+AVD | ABVD | Total |
|---|---|---|---|
| Female | 286 | 272 | 558 |
| Male | 378 | 398 | 776 |
| Ethnicity (NIH/OMB)(Participants) | A+AVD | ABVD | Total |
|---|---|---|---|
| Hispanic or Latino | 51 | 55 | 106 |
| Not Hispanic or Latino | 571 | 577 | 1148 |
| Unknown or Not Reported | 42 | 38 | 80 |
| Race (NIH/OMB)(Participants) | A+AVD | ABVD | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 56 | 57 | 113 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 20 | 25 | 45 |
| White | 560 | 554 | 1114 |
| More than one race | 18 | 17 | 35 |
| Unknown or Not Reported | 10 | 17 | 27 |
Showing the first 100 of 215 sites across 21 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Nov 2012 to primary completion in Apr 2017, 53 months.
Results were first posted in Nov 2018, 1 year 7 months after primary completion.
Of 33 phase 3 interventional studies under Hodgkin Disease, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 108. This study's 53 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brentuximab Vedotin